Praluent

Product NDC
61755-020
11-digit product format
617550020
Labeler code
61755
Product ID
61755-020_ad540294-d141-4655-a97b-abc9ae2795a3
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
alirocumab
Dosage form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Labeler
Regeneron Pharmaceuticals, Inc.
Application
BLA125559
Marketing category
BLA
Marketing start
2020-12-01
Substance
ALIROCUMAB
Active strength
75 mg/mL
Pharmacologic classes
Antibodies, Monoclonal [CS], PCSK9 Inhibitor [EPC], PCSK9 Inhibitors [MoA]
NDC exclude flag
No
Listing certified through
2026-12-31
Current FDA listing
Yes

Additional Listing Data#

Finished product
Yes
Brand name base
Praluent
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
ALIROCUMAB75 mg/mL

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
PP0SHH6V16Internal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 4 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
1659156Internal RxNorm lookup
1659161Internal RxNorm lookup
1659182Internal RxNorm lookup
1659183Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
7bcfbac2-e8ac-4569-8edc-bcde3b1fd172Available on FDA.report

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
ab434c1f-2b4e-461c-92e8-506132dea02aProduct name120190716
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324

FDA-Initiated Inactive NDC Indexing#

NDC, Related label table
NDCRelated label
61755-020-01These highlights do not include all the information needed to use PRALUENT safely and effectively. See full prescribing information for PRALUENT. PRALUENT ® (alirocumab) injection, for subcutaneous use Initial U.S. Approval: 2015
61755-020-01These highlights do not include all the information needed to use PRALUENT safely and effectively. See full prescribing information for PRALUENT. PRALUENT ® (alirocumab) injection, for subcutaneous use Initial U.S. Approval: 2015
61755-020-01These highlights do not include all the information needed to use PRALUENT safely and effectively. See full prescribing information for PRALUENT. PRALUENT ® (alirocumab) injection, for subcutaneous use Initial U.S. Approval: 2015
61755-020-02These highlights do not include all the information needed to use PRALUENT safely and effectively. See full prescribing information for PRALUENT. PRALUENT ® (alirocumab) injection, for subcutaneous use Initial U.S. Approval: 2015
61755-020-02These highlights do not include all the information needed to use PRALUENT safely and effectively. See full prescribing information for PRALUENT. PRALUENT ® (alirocumab) injection, for subcutaneous use Initial U.S. Approval: 2015
61755-020-02These highlights do not include all the information needed to use PRALUENT safely and effectively. See full prescribing information for PRALUENT. PRALUENT ® (alirocumab) injection, for subcutaneous use Initial U.S. Approval: 2015
61755-020-04These highlights do not include all the information needed to use PRALUENT safely and effectively. See full prescribing information for PRALUENT. PRALUENT ® (alirocumab) injection, for subcutaneous use Initial U.S. Approval: 2015
61755-020-04These highlights do not include all the information needed to use PRALUENT safely and effectively. See full prescribing information for PRALUENT. PRALUENT ® (alirocumab) injection, for subcutaneous use Initial U.S. Approval: 2015
61755-020-04These highlights do not include all the information needed to use PRALUENT safely and effectively. See full prescribing information for PRALUENT. PRALUENT ® (alirocumab) injection, for subcutaneous use Initial U.S. Approval: 2015

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
61755-020-01Praluent1 in 1 CARTONINJECTION, SOLUTION19
61755-020-01Praluent1 mL in 1 SYRINGE, GLASSINJECTION, SOLUTION19
61755-020-02Praluent1 mL in 1 SYRINGE, GLASSINJECTION, SOLUTION19
61755-020-02Praluent2 in 1 CARTONINJECTION, SOLUTION29
61755-020-04Praluent1 mL in 1 SYRINGE, GLASSINJECTION, SOLUTION19
61755-020-04Praluent1 in 1 CARTONINJECTION, SOLUTION19

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
61755-020-01ML - Milliliter61755-02055bd1300-6560-485b-95f1-bc981be49ad912022-09-12
61755-020-02ML - Milliliter61755-0206877d2c3-fe63-467e-b784-922540be618212021-04-08

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
61755-020PRALUENT (ALIROCUMAB) INJECTION, SOLUTION [REGENERON PHARMACEUTICALS, INC.]7Current NDC, Legacy NDC, 6 package rows20240405_7bcfbac2-e8ac-4569-8edc-bcde3b1fd172.zip

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
PraluentALIROCUMABRegeneron Pharmaceuticals, Inc.7bcfbac2-e8ac-4569-8edc-bcde3b1fd1722026-07-16Warnings, Adverse reactionsExact identifier
application number: BLA125559
ndc (product): 61755-020
PraluentALIROCUMABSanofi-Aventis U.S. LLC446f6b5c-0dd4-44ff-9bc2-c2b41f2806b42026-07-07Warnings, Adverse reactionsExact identifier
application number: BLA125559

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125559Praluentalirocumab351(a)Rx2026-08-01

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
1659156alirocumab 150 MG in 1 ML Auto-InjectorPSN7bcfbac2-e8ac-4569-8edc-bcde3b1fd1729
1659182alirocumab 75 MG in 1 ML Auto-InjectorPSN7bcfbac2-e8ac-4569-8edc-bcde3b1fd1729
1659161Praluent 150 MG in 1 ML Auto-InjectorPSN7bcfbac2-e8ac-4569-8edc-bcde3b1fd1729
1659183Praluent 75 MG in 1 ML Auto-InjectorPSN7bcfbac2-e8ac-4569-8edc-bcde3b1fd1729
16591611 ML alirocumab 150 MG/ML Auto-Injector [Praluent]SBD7bcfbac2-e8ac-4569-8edc-bcde3b1fd1729
16591831 ML alirocumab 75 MG/ML Auto-Injector [Praluent]SBD7bcfbac2-e8ac-4569-8edc-bcde3b1fd1729
16591561 ML alirocumab 150 MG/ML Auto-InjectorSCD7bcfbac2-e8ac-4569-8edc-bcde3b1fd1729
16591821 ML alirocumab 75 MG/ML Auto-InjectorSCD7bcfbac2-e8ac-4569-8edc-bcde3b1fd1729
16591611 ML Praluent 150 MG/ML Auto-InjectorSY7bcfbac2-e8ac-4569-8edc-bcde3b1fd1729
16591831 ML Praluent 75 MG/ML Auto-InjectorSY7bcfbac2-e8ac-4569-8edc-bcde3b1fd1729
1659156alirocumab 150 MG per 1 ML Auto-InjectorSY7bcfbac2-e8ac-4569-8edc-bcde3b1fd1729
1659182alirocumab 75 MG per 1 ML Auto-InjectorSY7bcfbac2-e8ac-4569-8edc-bcde3b1fd1729
1659161Praluent 150 MG per 1 ML Auto-InjectorSY7bcfbac2-e8ac-4569-8edc-bcde3b1fd1729
1659183Praluent 75 MG per 1 ML Auto-InjectorSY7bcfbac2-e8ac-4569-8edc-bcde3b1fd1729

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startMarketing endSampleExclude flagStatus
61755-020-01617550020011 SYRINGE, GLASS in 1 CARTON (61755-020-01) / 1 mL in 1 SYRINGE, GLASS2020-12-010000-00-00NoNoCurrent
61755-020-02617550020022 SYRINGE, GLASS in 1 CARTON (61755-020-02) / 1 mL in 1 SYRINGE, GLASS2020-12-010000-00-00NoNoCurrent
61755-020-04617550020041 SYRINGE, GLASS in 1 CARTON (61755-020-04) / 1 mL in 1 SYRINGE, GLASS2020-12-010000-00-00YesNoCurrent